이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Austar Lifesciences 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mars Ho

최고 경영자

CN¥935.0k

총 보상

CEO 급여 비율	98.3%
CEO 임기	10.7yrs
CEO 소유권	66.3%
경영진 평균 재임 기간	10.3yrs
이사회 평균 재임 기간	10.3yrs

최근 관리 업데이트

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

May 24

Recent updates

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

Aug 28

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

May 24

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Mar 28

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23

CEO 보상 분석

Mars Ho 의 보수는 Austar Lifesciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥19m
Mar 31 2024	n/a	n/a	-CN¥26m
Dec 31 2023	CN¥935k	CN¥919k	-CN¥33m
Jun 30 2023	n/a	n/a	CN¥51m
Mar 31 2023	n/a	n/a	CN¥78m
Dec 31 2022	CN¥895k	CN¥880k	CN¥104m
Sep 30 2022	n/a	n/a	CN¥96m
Jun 30 2022	n/a	n/a	CN¥105m
Mar 31 2022	n/a	n/a	CN¥191m
Dec 31 2021	CN¥865k	CN¥850k	CN¥277m
Sep 30 2021	n/a	n/a	CN¥258m
Jun 30 2021	n/a	n/a	CN¥238m
Mar 31 2021	n/a	n/a	CN¥136m
Dec 31 2020	CN¥927k	CN¥911k	CN¥33m
Sep 30 2020	n/a	n/a	CN¥25m
Jun 30 2020	n/a	n/a	CN¥17m
Mar 31 2020	n/a	n/a	CN¥12m
Dec 31 2019	CN¥918k	CN¥902k	CN¥8m
Sep 30 2019	n/a	n/a	CN¥8m
Jun 30 2019	n/a	n/a	CN¥8m
Mar 31 2019	n/a	n/a	CN¥4m
Dec 31 2018	CN¥880k	CN¥865k	CN¥107k
Sep 30 2018	n/a	n/a	-CN¥16m
Jun 30 2018	n/a	n/a	-CN¥33m
Mar 31 2018	n/a	n/a	-CN¥43m
Dec 31 2017	CN¥1m	CN¥1m	-CN¥54m

보상 대 시장: Mars 의 총 보상 ($USD 128.79K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 232.88K ).

보상과 수익: 회사가 수익성이 없는 동안 Mars 의 보상이 증가했습니다.

CEO

Mars Ho (62 yo)

10.7yrs

테뉴어

CN¥935,000

보상

Mr. Kwok Keung Ho, also known as Mars, is the Founder of Austar Lifesciences Limited and serves as its Chairman of the Board and Chief Executive Officer. Mr. Ho is responsible for overseeing the business,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kwok Keung Ho	Founder	no data	CN¥935.00k	66.27% CN¥ 214.0m
Yuewu Chen	Executive Director	10.3yrs	CN¥2.13m	데이터 없음
Ning Zhou	Executive Director	10.3yrs	CN¥1.11m	데이터 없음
Kin Hung Ho	Executive Director	10.3yrs	CN¥2.26m	7.27% CN¥ 23.5m
Xiangdi Tang	Vice President of Corporate Development	3.8yrs	데이터 없음	데이터 없음
Yuk Kiu Mak	Company Secretary	1.9yrs	데이터 없음	데이터 없음

10.3yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: 6118 의 관리팀은 노련하고 경험 (평균 재직 기간 10 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kwok Keung Ho	Founder	10.7yrs	CN¥935.00k	66.27% CN¥ 214.0m
Yuewu Chen	Executive Director	10.3yrs	CN¥2.13m	데이터 없음
Ning Zhou	Executive Director	10.3yrs	CN¥1.11m	데이터 없음
Kin Hung Ho	Executive Director	10.7yrs	CN¥2.26m	7.27% CN¥ 23.5m
Lap Kei Cheung	Independent Non-Executive Director	9.9yrs	CN¥161.00k	데이터 없음
Oi Kin Leung	Independent Non-Executive Director	6.9yrs	CN¥161.00k	데이터 없음
Hoi Shan Chiu	Independent Non-Executive Director	9.9yrs	CN¥161.00k	데이터 없음
Lingling Ji	Non-Executive Director	10.3yrs	CN¥632.00k	데이터 없음

10.3yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 이사회: 6118 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10 년).

Austar Lifesciences 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

Austar Lifesciences Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Austar Lifesciences Limited Announces Executive Changes

Less than half of directors are independent

Recent updates

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

First half 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.078 loss in 1H 2023)

Austar Lifesciences Limited to Report First Half, 2024 Results on Aug 27, 2024

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Austar Lifesciences Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: CN¥0.063 loss per share (vs CN¥0.17 profit in FY 2022)

Austar Lifesciences Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

New major risk - Share price stability

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

First half 2023 earnings released: CN¥0.078 loss per share (vs CN¥0.089 profit in 1H 2022)

Investor sentiment deteriorates as stock falls 30%

Austar Lifesciences Limited to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 25%

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.54 in FY 2021)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 25%

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Austar Lifesciences Limited Announces Executive Changes

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

First half 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.42 in 1H 2021)

Investor sentiment deteriorated over the past week

Austar Lifesciences Limited to Report First Half, 2022 Results on Aug 29, 2022

Austar Lifesciences Limited (SEHK:6118) acquired an unknown minority interest in Noozle Fluid Technology (Shanghai) Co., Ltd..

Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Less than half of directors are independent

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Investor sentiment improved over the past week

Austar Lifesciences Limited Provides Group Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorated over the past week

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

First half 2021 earnings released: EPS CN¥0.42 (vs CN¥0.025 in 1H 2020)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Full year 2020 earnings released: EPS CN¥0.065 (vs CN¥0.016 in FY 2019)

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.06 (vs CN¥0.016 in FY 2019)

Austar Lifesciences Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

An affiliate of Pall Corporation entered into an agreement to acquire 60% in PALL-AUSTAR Lifesciences Limited from Austar Lifesciences Limited (SEHK:6118) for approximately CNY 220 million.

New 90-day high: HK$6.15

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

New 90-day high: HK$4.02

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

First half earnings released

New 90-day low - HK$3.18

First half earnings released

Austar Lifesciences Limited to Report First Half, 2020 Results on Aug 27, 2020

New 90-day low - HK$3.23

CEO 보상 분석

CEO

테뉴어